World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
142
Citations
95109
World Ranking
1542
National Ranking
896

Overview

Moshe Talpaz is affiliated with the University of Michigan-Ann Arbor in the United States. Their primary field of study is medicine, with a significant focus on hematology, genetics, and molecular biology. They also have research involvement in rheumatology and public health, environmental, and occupational health.

The scientist's work concentrates on topics related to hematologic malignancies and treatments. Key research topics associated with their publications include:

  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Acute Myeloid Leukemia Research
  • Kruppel-like factors research
  • Eosinophilic Disorders and Syndromes

Among their recent papers are:

  • Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis, 2020, Leukemia
  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial, 2021, Blood
  • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors, 2021, JAMA Oncology
  • Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure, 2020, American Journal of Hematology

Talpaz has frequently collaborated with several coauthors, notably Claire Harrison, Ruben A. Mesa, Vikas Gupta, Jean-Jacques Kiladjian, and John Mascarenhas.

Their research outputs have been published in several venues, with frequent publications appearing in:

  • Clinical Lymphoma Myeloma & Leukemia
  • Blood
  • HemaSphere
  • Leukemia
  • Blood Advances

Best Publications

  • Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

    Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng

  • Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

    Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • The biology of chronic myeloid leukemia

    Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

    M. S. Gordon;K. Margolin;M. Talpaz;G. W. Sledge

  • Activating ESR1 mutations in hormone-resistant metastatic breast cancer

    Dan R. Robinson;Yi Mi Wu;Pankaj Vats;Fengyun Su

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias

    Razelle Kurzrock;Jordan U. Gutterman;Moshe Talpaz

  • Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaA in Chronic Myelogenous Leukemia

    Moshe Talpaz;Hagop M. Kantarjian;Kenneth McCredie;Jose M. Trujillo

  • Integrative clinical genomics of metastatic cancer

    Dan R. Robinson;Yi Mi Wu;Robert J. Lonigro;Pankaj Vats

  • BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

    Nicholas J. Donato;Ji Yuan Wu;Jonathan Stapley;Gary Gallick

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

    Dan R. Robinson;Yi Mi Wu;Shanker Kalyana-Sundaram;Shanker Kalyana-Sundaram;Xuhong Cao

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Clinical toxicity of interferons in cancer patients: a review.

    Jorge R. Quesada;Moshe Talpaz;Adan Rios;Razelle Kurzrock

  • Identification of Targetable FGFR Gene Fusions in Diverse Cancers

    Yi Mi Wu;Fengyun Su;Shanker Kalyana-Sundaram;Nickolay Khazanov

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Michael W. Deininger
Michael W. Deininger University of Utah
Susan O'Brien
Susan O'Brien University of California, Irvine
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Neil P. Shah
Neil P. Shah University of California, San Francisco
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up a variety of related online degrees and career paths within the healthcare sector. For those interested in healthcare administration, there are cheap mha programs that offer flexibility and affordability while developing crucial leadership skills.

Nurses looking to advance their careers can benefit from the most affordable dnp programs available online, enabling them to earn a Doctor of Nursing Practice degree without the burden of high tuition costs.

Pharmacy is another growing field. Aspiring pharmacists can consider accredited online pharmacy schools that provide convenience for working professionals or those with busy schedules.

Finally, if you’re interested in the information technology side of healthcare, online rhit degree programs are an excellent gateway into health information management, a field in high demand for its role in modern medical environments.

Exploring these online pathways offers flexibility, affordability, and specialized training—all essential factors for today’s evolving medical careers.

Best Scientists Citing Moshe Talpaz

Trending Scientists

Recently Published Articles